Investigational drug · Phase 3
Intravitreal Ranibizumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Macular Edema.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
461
Any phase or sponsor naming "Intravitreal Ranibizumab"
First trial start
2019
Sep 30, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Intravitreal Ranibizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema
Approved drugs for the same conditions: Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Intravitreal Ranibizumab" as an intervention, largest first.
- Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00637377 · 1,240 participants · Start Apr 2008 · Primary completion Sep 2010
Drug: Ranibizumab; Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Rosario, Argentina · 189 sites in all
- Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00509795 · 1,217 participants · Start Aug 2007 · Primary completion Sep 2010
Drug: ranibizumab; aflibercept injection (VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 188 sites in all
- Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin TrialPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT00593450 · 1,208 participants · Start Feb 2008 · Primary completion Dec 2010
Drug: ranibizumab; bevacizumab · For: Age Related Macular Degeneration
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 59 sites in all
- A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00891735 · 1,097 participants · Start Jul 2009 · Primary completion Aug 2011
Drug: Ranibizumab · For: Age-related Macular Degeneration
Sites: Phoenix, Arizona; Tucson, Arizona; Arcadia, California · 99 sites in all
- A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPivotal-lookingActive, not recruiting
EyeBiotech Ltd.Industry
NCT06957080 · 1,054 participants · Start Apr 16, 2025 · Primary completion Jan 11, 2027
Drug: Remigromig; Ranibizumab · For: Diabetic Macular Edema (DME)
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 164 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01986907 · 1,049 participants · Start Mar 4, 2014 · Primary completion Jun 15, 2016
Drug: ranibizumab · For: Wet Age Related Macular Degeneration
Sites: Alessandria, Italy; Casale Monferrato, Italy; Ancona, Italy · 101 sites in all
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT02081339 · 1,000 participants (planned) · Start Mar 2014 · Primary completion Mar 2022
Drug: ranibizumab, aflibercept, pegaptanib, verteporphin · For: Macular Disease
Sites: Kyoto, Japan
- Extension Study for the Port Delivery System With Ranibizumab (Portal)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03683251 · 1,000 participants (planned) · Start Sep 20, 2018 · Primary completion Dec 31, 2029
Drug: PDS Implant with Ranibizumab 100 mg/mL · For: Neovascular Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 165 sites in all
Kagawa UniversityAcademic, hospital or other
NCT02321267 · 1,000 participants (planned) · Start Dec 2014 · Primary completion Dec 2024
Drug: ranibizumab, aflibercept, pegaptanib, verteporphin · For: Macular Disease
Sites: Hiragi, Japan
- Anti-VEGF in Real-worldStatus unknown
Wenbin WeiAcademic, hospital or other
NCT05222633 · 1,000 participants (planned) · Start Jan 1, 2022 · Primary completion Jan 1, 2023
Drug: Ranibizumab; Aflibercept and 1 more · For: Neovascular Age-related Macular Edema; Diabetic Macular Edema; Choroidal Neovascular Membrane and 3 more
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.
Sakai T, Ishibashi R, Koshizaka M, et al. · Diabetes Obes Metab 2026
- Platelet parameters and treatment-requiring reactivation after intravitreal ranibizumab for retinopathy of prematurity: a retrospective single-center study.
Zhou Y, Xiao B, Wang S · Graefes Arch Clin Exp Ophthalmol 2026
- Intravitreal dexamethasone implant-based versus ranibizumab-based regimens for stage 3 Coats' disease: Efficacy and complications.
Zhang J, Zhang M, Yang Q, et al. · Acta Ophthalmol 2026
- Visual and Anatomical Outcomes of Intravitreal Ranibizumab Combined with Focal/Grid Macular Laser for Center-Involved Diabetic Macular Edema: A Real-World Retrospective Cohort Study.
Xie J, Zhang Y, Peng Q, et al. · Ophthalmic Epidemiol 2026
- Incidence rate and factors associated with periprocedural hypoxia during bedside intravitreal ranibizumab injection for retinopathy of prematurity: a multicenter retrospective study.
Al-Hadlaq AM, Nagy WMA, Elwan SAM · BMC Ophthalmol 2026
- Port Delivery System Vs Monthly Ranibizumab in VEGF-Driven Macular Disease: A Systematic Review and Meta-Analysis.
Dogru E, Chavez MP, Toth O, et al. · Semin Ophthalmol 2026
Also in development for Diabetic Macular Edema
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OCS-01Phase 32 trials
Oculis · Diabetic Macular Edema
- AVT29proposed aflibercept HD biosimilarPhase 31 trial
Alvotech Swiss AG · Diabetic Macular Edema
- BI 3812465Phase 21 trial
Boehringer Ingelheim · Diabetic Macular Edema
- CU06-1004Phase 21 trial
Curacle Co., Ltd. · DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)
- OXU-001DEXAspheresPhase 21 trial
Oxular Limited · Diabetic Macular Edema
- RO7446603Phase 21 trial
Roche (Genentech) · Diabetic Macular Edema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.